Logo of REPROCELL

REPROCELL

Our portfolio includes an extensive product catalog to support stem cell research and 3D bioengineered tissues, a commercial biorepository of ethically-sourced human tissue samples, extensive clinical networks across the USA and Europe that enable our contract research services in human ex vivo living tissues, and our capability to supply induced pluripotent stem cells (iPSCs) for both clinical stem cell and research stem cell applications.  
We are also developing novel regenerative medicine therapies to treat neurodegenerative disease, based on our expertise in pluripotent stem cells and mesenchymal stem cells, and we are currently conducting clinical trials in Japan for the treatment of spinocerebellar ataxia. Our diagnostic services and clinical research services are offered across labs in Japan, USA, UK, and India.
Our expertise in patient recruitment, the logistics, and ethics of accessing human biospecimens and diagnostics is driving the development of new technologies to support biomarker research and precision medicine. Combined with our clinical laboratory facilities, these resources and know-how have positioned REPROCELL as a fully integrated partner for the life sciences industry, with clients across the globe.

Content by REPROCELL

Multiple spherical stem cells in various sizes, suspended in a vivid blue environment
| 2 min read
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up of a researcher using a stylus to draw or interact with digital molecular structures on a blue scientific interface.
When molecules outgrow the limits of sketches and strings, researchers need a new way to describe and communicate them.
Portrait of Scott Weitze, Vice President of Research and Technical Standards at My Green Lab, beside text that reads “Tell us what you know: Bringing sustainability into scientific research,” with the My Green Lab logo.
Laboratories account for a surprising share of global emissions and plastic waste, making sustainability a priority for modern research.
3D illustration of RNA molecules on a gradient blue background.
With diverse emerging modalities and innovative delivery strategies, RNA therapeutics are tackling complex diseases and unmet medical needs.
Drug Discovery News September 2025 Issue
Latest IssueVolume 21 • Issue 3 • September 2025

September 2025

September 2025 Issue

Explore this issue